Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Contact: Dr Claire Powers, Viral Vector Core Facility Manager 

Jenner Institute, Centre for Cellular and Molecular Physiology

Roosevelt Drive, Oxford OX3 7BN

Tel: +44 (0)1865 287761

Email: claire.powers@ndm.ox.ac.uk

Background

The Viral Vector Core Facility (VVCF) at the Jenner Institute has been producing all recombinant viral vectors required by Jenner Investigators for pre-clinical vaccine studies and other purposes for over a decade. The facility is also able to supply external academic and industrial collaborators subject to confirmation that there are no conflicts of interest with current Jenner Institute research programmes.Louonscope.JPG

A major bottleneck in vector use and development has been the small number of scientists with access to expertise in generation of recombinant viral vectors. The purpose of the VVCF is to generate recombinant vectors in adequate yield and quality for pre-clinical and veterinary research. Our vectors have been used in a wide range of animal models including; mice, non-human primates, sheep, cattle / buffalo, chickens, elephants, goats, camels, rabbits, guinea pigs and rats.

We are a small team of experienced and dedicated staff providing small to medium scale viral preparations of high quality at low cost. We save our end users time and provide peace of mind that projects are started using materials that are viable and correct.vvc-ali-merge.jpeg


 

ADENOVIRAL vectors

VVCF provide adenoviral preps of 1-5x1010 IU in total (1-2x1012 VP) for a standard batch and each batch is subjected to our standard QC tests. Large scale batches (1x1012 IU+) can be prepared upon request.

Insert size: up to 6.5kb.bandextract2.JPG

Adenoviral vectors available: AdHu5 constructs or the Oxford owned ChAdOx1 and ChAdOx2 vectors.

Timescale: from linearized BAC to final product in less than 8 weeks.

Cost: approx. £700 for a standard prep (administration and shipping charges also apply). VVCF also offer molecular biology services to produce the starting material required for viral production for an additional fee.

 

 

MODIFIED VACCINIA ANKARA (mva) VECTORS:

Minimum batch yield of 5x108 to 1x109 total PFU. Each batch is subjected to our standard QC tests.

Insert size: up to 10kb.

MVA vectors available: antigen expression at either the F11 locus (Oxford patented) or the TK locus (freely available), with or without a fluorescent marker (mCherry or GFP).Tissueculturealka.JPG

Timescale: from plasmid to final product in 12-14 weeks.

Cost: Prices start from £1,500 per batch. VVCF can also produce the starting material required for production on request for an additional fee.

Pre-GMP MVA: VVCF are able to produce MVA seed stock suitable for use as a starting material in your GMP process. Please contact us for more details.  

 

 

QUALITY CONTROL TESTING:

Our standard QC tests for batches are:

 Identity:               Flank to flank PCR to ensure correct size of antigen insert (adeno / MVA)Picture1.png

                             ID specific PCR (adeno / MVA)

                             Purity PCR to ensure absence of parental virus (MVA)

Viral titre:              Viral particle (VP) measurement by spec (adeno)

                             Infectious units (IU) by immune-titration (adeno)

                             Plaque forming units (PFU) (MVA)superM.JPG

Sterility testing:    Broth culture method.

 

You will receive full batch paperwork detailing the origin, production details and QC information. 

VVCF are also able to offer end-point sequencing of all final products and stability testing for adenoviruses over 5 to 10 passages with or without repression (with or without sequencing).

 

MOLECULAR BIOLOGY SERVICES:

By request, VVCF can order a desired insert (as a plasmid) and perform the necessary molecular work to produce the starting materials required for virus production. Beckybacteria.JPG

All plasmids and BACs produced at VVCF undergo full flank-to-flank sequencing to confirm the antigen sequence is correct prior to production.

 

 

 

RE-BULKS AND LARGE BULK ORDERS:

Once a virus has been prepared at VVCF we retain a pre-master seed for convenience of future orders. We are also able to produce viral batches on a larger scale that the standard prep sizes given. Please contact us for a fullvaccineshot.JPG quotation.

 

 

 

 

 

 

We welcome opportunities for collaboration or business partnership; enquiries can be directed to Dr Claire Powers: claire.powers@ndm.ox.ac.uk.